CRISPR: Downside BiasCRISPR extended its correction over the past few weeks, although the downside momentum has eased somewhat more recently. For now, we primarily expect a sell-off below the support at $30.02. Once a low is established there, the stock should move higher again. Alternatively, the shares could post another temporary rebound first. In that case, price would briefly break above the resistance at $61.76 to establish a new corrective high (probability: 34%).
